hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06276907 id: ILBS-ACLF-16 briefTitle: An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2027-12-31 date: 2027-12-31 date: 2024-02-26 date: 2024-02-26 name: Institute of Liver and Biliary Sciences, India class: OTHER briefSummary: Rationale: Current understanding of the pathophysiology of ACLF suggests that unresolved injury, poor infection control, and liver regeneration result in persistent systemic inflammation and cytokine storm, which subsequently lead to systemic inflammatory response syndrome (SIRS) resulting in multiple organ failures, septic shock and deaths in ACLF. Nearly 74% of ACLF patients initially diagnosed without SIRS, sepsis, or organ failure developed SIRS by day 7 which increases the onset of secondary organ failure and sepsis with high short-term mortality. The emerging use of plasma exchange has shown some potential benefits in terms of dampening systemic inflammation and improvement of outcomes in some ACLF patients. However, there is currently no randomized controlled trial exploring the potential role in ameliorating secondary organ dysfunctions in patients with ACLF is not known. Hence in the current objective, we want to study the role of plasma exchange in the management of sec. organ failure in ACLF patients in a randomized controlled trial and identify the biomarker to access the treatment response to therapy. conditions: Acute on Chronic Liver Failure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 190 type: ESTIMATED name: Plasma Exchange name: Standard Medical Treatment measure: The AARC grading is done by AARC score the values of which vary from 5-15 , pts are divided into 3 grades i.e AARC score 5-7- grade 1, 8-10- grade 2, and AARC 11-15 as grade 3. Improvement in 1 grade is associated with 40% improvement in 28-day survival measure: Transplant-free survival at 28-days measure: The impact of TPE on the progression or resolution of secondary organ failures at day 7, 14 and 28 measure: the development of infection at day 7 and 14 in patients who had no infection measure: Duration of ICU and hospital stay measure: The proportion of patients developing adverse events will be compared between the two groups sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute of Liver & Biliary Sciences city: New Delhi state: Delhi zip: 110070 country: India name: Dr Rakhi Maiwall, DM role: CONTACT phone: 01146300000 email: rakhi_2011@yahoo.co.in lat: 28.63576 lon: 77.22445 hasResults: False
nctId: NCT06276894 id: IRB #2064530-1 briefTitle: Functional Near-Infrared Spectroscopy (fNIRS) Assessing Neural Activity During Virtual Reality Walking Intervention acronym: fNIRS overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-02-01 date: 2025-02-01 date: 2024-02-26 date: 2024-02-26 name: Craig Hospital class: OTHER briefSummary: The purpose of this study is to evaluate the safety and feasibility of using a portable neuroimaging device called functional near-infrared spectroscopy (fNIRS) to successfully analyze fNIRS data in individuals with chronic TBI during treadmill training augmented with VR. conditions: Traumatic Brain Injury studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 15 type: ESTIMATED name: Motek C-Mill™ treadmill name: training session with and without VR wearing the fNIRS cap measure: Incidence of Treatment-Related Adverse Events (e.g., Safety and Tolerability) measure: Acceptability of the intervention measure: fNIRS Data Quality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Craig Hospital city: Englewood state: Colorado zip: 80113 country: United States lat: 39.64777 lon: -104.98776 hasResults: False
nctId: NCT06276881 id: DSC1001 id: 1R43DA054845-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R43DA054845-01 briefTitle: Visual Stimulation for Pain Relief overallStatus: COMPLETED date: 2022-06-03 date: 2022-12-28 date: 2023-05-01 date: 2024-02-26 date: 2024-04-03 date: 2024-04-03 name: Dandelion Science class: INDUSTRY name: National Institutes of Health (NIH) name: National Institute on Drug Abuse (NIDA) briefSummary: The goal of this study is to investigate a novel neuromodulatory approach utilizing visual stimulation to impact pain perception in healthy participants. conditions: Pain studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 75 type: ACTUAL name: Visual Stimulation measure: Visual Analog Scale (VAS) Score measure: Event-related Potential (ERP) sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Dandelion Science city: Hoboken state: New Jersey zip: 07030 country: United States lat: 40.74399 lon: -74.03236 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2021-12-21 uploadDate: 2024-03-08T12:20 filename: Prot_SAP_000.pdf size: 689133 hasResults: True
nctId: NCT06276868 id: HELEN-017 briefTitle: Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-07-01 date: 2029-06-01 date: 2024-02-26 date: 2024-02-26 name: Henan Cancer Hospital class: OTHER_GOV briefSummary: This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before surgery. It is intended to further explore the efficacy and safety of the new adjuvant treatment for TPBC patients with step-down therapy. conditions: Breast Cancer conditions: HER2-positive Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, single arm clinical study primaryPurpose: TREATMENT masking: NONE count: 66 type: ESTIMATED name: Dalcilib+letrozole+HP treatment group measure: pathologic complete response measure: Adverse event occurrence measure: objective response rate measure: Residual cancer burden measure: Event free survival measure: Disease free survival measure: Distant disease/recurrence free survival sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Henan cacer hospital city: Henan state: Henan zip: 450008 country: China hasResults: False
nctId: NCT06276855 id: CUtülay briefTitle: Sleep Hygiene Education in Individuals With Fibromyalgia; Sleep Quality, Pain and Depression overallStatus: COMPLETED date: 2021-06-23 date: 2021-07-01 date: 2021-12-31 date: 2024-02-26 date: 2024-02-26 name: Cumhuriyet University class: OTHER briefSummary: Objective: This semi-experimental study was conducted to determine the effect of sleep hygiene education on sleep quality, pain, and depression in individuals with fibromyalgia.
Patients and methods: A sample of 70 individuals with fibromyalgia (35 experimental, 35 control) were included in the study. Data was collected using the Pittsburgh Sleep Quality Index, the Visual Analog Scale, and the Beck Depression Inventory. conditions: Fibromyalgia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Experimental group Control group primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 70 type: ACTUAL name: Sleep hygiene education measure: Demographic Information Form (DIF). measure: Pittsburgh Sleep Quality Index (PSQI). measure: Visual Analog Scale (VAS). measure: Beck Depression Inventory (BDI). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sivas Cumhuriyet University city: Sivas state: Center zip: 58140 country: Turkey lat: 39.74833 lon: 37.01611 hasResults: False
nctId: NCT06276842 id: 12345678 briefTitle: Efficacy of Combining an Inferior Alveolar Nerve Block With a Buccal Infiltration overallStatus: COMPLETED date: 2020-04-01 date: 2020-09-30 date: 2020-09-30 date: 2024-02-26 date: 2024-02-26 name: CIMS Dental College class: OTHER briefSummary: OBJECTIVE To compare the effectiveness of using both a combined technique of an Inferior Alveolar Nerve block and buccal infiltration with that achieved by utilizing an Inferior Alveolar Nerve block alone for endodontic treatment of mandibular molars with irreversible pulpitis.
MATERIAL AND METHODS A total of 120 patients were enrolled in the study. Sixty patients of group A received conventional Inferior Alveolar Nerve block and sixty patients of Group B received buccal infiltration along with conventional Inferior Alveolar Nerve block. conditions: Pulpitis studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 120 type: ACTUAL name: Inferior Alveolar Nerve Block name: Buccal Infiltration name: Inferior Alveolar Nerve Block and Buccal Infiltration measure: Comparison of Anesthesia Effectiveness Between Combined Technique (Inferior Alveolar Nerve Block and Buccal Infiltration) and Inferior Alveolar Nerve Block Alone sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Dr Ayesha Ahmed city: Multan country: Pakistan lat: 30.19679 lon: 71.47824 hasResults: False
nctId: NCT06276829 id: 02.05.2023/291 briefTitle: Behçet and LDH/Albumin overallStatus: COMPLETED date: 2020-02-01 date: 2023-04-01 date: 2023-04-01 date: 2024-02-26 date: 2024-02-26 name: Ataturk University class: OTHER briefSummary: ABSTRACT Objective: To investigate whether the lactate dehydrogenase to albumin ratio can be used as a parameter to determine disease severity in Behçet's disease, an inflammatory disease, by comparing it to healthy controls.
Patients and Methods: In this retrospective cohort study, patients with Behçet's disease aged 18-69 years who presented to the outpatient clinic between February 2020 and April 2023 and healthy individuals of similar age and gender were enrolled. LDH, albumin levels, and LDH/albumin ratio of both groups were compared. Clinical findings and characteristics of Behçet's patients and disease severity were recorded and analyzed in relation to LDH/albumin ratio. conditions: Behcet's Disease conditions: Albumin conditions: Lactate Dehydrogenase conditions: Disease Severity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 1 type: ACTUAL name: LDH/albumin ratio measure: LDH/albumin ratio sex: ALL minimumAge: 18 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erdal Pala city: Erzurum zip: 25240 country: Turkey lat: 39.90861 lon: 41.27694 hasResults: False
nctId: NCT06276816 id: 2022-LC14 briefTitle: Cardiac Denervation Ablation Strategy for Severe Sinus Bradycardia overallStatus: RECRUITING date: 2023-09-13 date: 2024-09-30 date: 2024-12-30 date: 2024-02-26 date: 2024-02-26 name: China National Center for Cardiovascular Diseases class: OTHER_GOV briefSummary: This is a prospective clinical observation and registration study. The investigator aimed to evaluate the efficacy and safety of cardiac denervation ablation as a treatment strategy for severe sinus bradycardia. conditions: Sinus Bradycardia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 88 type: ESTIMATED measure: Number of patients with postoperative recurrence of bradycardia symptoms measure: The result of the atropine test measure: Changes in quality of life measured by Medical Outcomes Study 36- Item Short Form Health Survey (SF-36) measure: Changes in quality of life measured by EuroQol Five Dimensions Questionnaire Visual Analogue Scale (EQ VAS) measure: Changes in minmum heart rate measure: Changes in mean heart rate measure: Changes in deceleration capacity sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: 1Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College status: RECRUITING city: Beijing country: China name: Yao Yan, MD PhD role: CONTACT phone: +86-1390-1121-319 email: ianyao@263.net.cn lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06276803 id: Adenocyte 104 briefTitle: The LINFU® U.S. Registry for the in the General Population Without Risk Factors overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2034-04-15 date: 2034-06-15 date: 2024-02-26 date: 2024-03-06 name: Adenocyte, LLC class: INDUSTRY briefSummary: Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions.. In this study, LINFU® will be evaluated in the general population with no risk factors and who exhibit no signs or symptoms of disease, This study will help determine if LINFU® can be used to help identify early, asymptomatic pancreatic ductal adenocarcinoma (PDAC) or their precursor lesions (PanIn-2, PanIn-3). conditions: Pancreatic Cancer conditions: Pancreatic Ductal Adenocarcinoma conditions: Pancreatic Dysplasia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: LINFU® measure: The number of pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified with LINFU® measure: The change in size of pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified with LINFU® will be determined long term measure: Determine the number of patients with early pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified with LINFU® that require medical or surgical intervention measure: Yearly survival rate of patients with early pancreatic ductal adenocarcinomas or their noninvasive precursor lesions identified with LINFU® sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06276790 id: ChengdeCentralHospital briefTitle: Objective Analysis of Caesarean Scar Pregnancy overallStatus: COMPLETED date: 2019-01-18 date: 2022-12-23 date: 2022-12-25 date: 2024-02-26 date: 2024-02-26 name: Chengde Central Hospital class: OTHER_GOV briefSummary: This study uses a systematic scoring method combined with clinical and ultrasound data to comprehensively evaluate patient conditions and explore the guiding value of the ultrasound quantitative scoring system for selecting the surgical approach for caesarean scar pregnancy. conditions: Caesarean Scar Pregnancy conditions: Ultrasound Scoring System studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 117 type: ACTUAL name: ultrasound-guided/hysteroscopic curettage name: Procedure/Surgery: laparoscopic removal of the pregnancy lesion measure: intraoperative blood loss measure: length of hospital stay measure: serum β-HCG levels sex: FEMALE minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chengde Central Hospital city: Chengde zip: 067000 country: China lat: 40.9519 lon: 117.95883 hasResults: False
nctId: NCT06276777 id: SPRG Dentin Hypersensitivity briefTitle: The Effect of Using Desensitizers Containing S-PRG In Treatment Of Dentin Hypersensitivity Over 6 Months: A Randomized Clinical Trial acronym: S-PRG overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-11-01 date: 2024-12-01 date: 2024-02-26 date: 2024-02-26 name: Eman Omar Elfarouk class: OTHER briefSummary: The goal of this clinical trial is to compare the effect of desensitizer containing S-PRG have similar effect as sodium fluoride with functionalized tri-calcium phosphate containing desensitizer in relieving dentinal hypersensitivity in adult patients for six months follow-up. patients will be asked to report pain degree on the visual analogue scale (VAS) along the follow up periods on both groups. conditions: Dentin Hypersensitivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Participants and both assessors will be blind to the type of material used. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Tooth varnish (PRG Barrier Coat from Shofu) name: Tooth varnish (Clinpro white varnish 3M) measure: Dentin hypersensitivity reduction sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Faculty of Dentistry Cairo University city: Cairo zip: 11331 country: Egypt name: Eman Omar, bachelor role: CONTACT phone: 01156677558 email: eman.omar@dentistry.cu.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06276764 id: Adenocyte 103 briefTitle: The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas) overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2034-03-30 date: 2034-05-01 date: 2024-02-26 date: 2024-02-26 name: Adenocyte, LLC class: INDUSTRY briefSummary: In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia). The study will also help determine if LINFU® results in earlier intervention, treatment and improvement in patient outcomes. conditions: IPMN, Pancreatic conditions: Pancreas Cancer conditions: Pancreatic Cyst studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: LINFU® name: Standard imaging tests measure: The number of pancreatic ductal adenocarcinomas or their precursor lesions, dysplasia, identified only with LINFU® will be compared to standard screening methods measure: The change in size of pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® will be determined over a 5 year period measure: Determine the number of patients with early pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® that require medical or surgical intervention. measure: Yearly survival rate of patients with early pancreatic ductal adenocarcinomas or their noninvasive precursor lesions identified only with LINFU® sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06276751 id: E1-23-3870 ptx endtidalco2 briefTitle: The Diagnostic Value of End-Tidal CO2 in Patients Diagnosed With Pneumothorax overallStatus: COMPLETED date: 2023-08-15 date: 2024-02-06 date: 2024-02-13 date: 2024-02-26 date: 2024-02-26 name: Ankara City Hospital Bilkent class: OTHER briefSummary: Pneumothorax (PTX) is defined as the accumulation of air in the pleural space. PTX can cause a disruption in the perfusion of lung tissue in the affected area and increase intrathoracic pressure, potentially leading to obstruction of venous return and, consequently, posing a life-threatening condition. Therefore, PTX requiring urgent intervention is a significant concern in emergency departments.
End-tidal carbon dioxide (ETCO2) provides insight into carbon dioxide levels resulting from lung perfusion and serves as a respiratory parameter informing the prognosis of various critical illnesses. One of the most important factors determining lung perfusion is the effective lung area. Among the crucial issues for emergency departments are PTX cases, which typically regress following urgent intervention, leading to the establishment of an effective lung area. Hypotheses have been proposed in the literature suggesting that ETCO2 may be affected in PTX cases due to the relationship between effective lung area and ETCO2.
In this study, investigetors aimed to investigate changes in ETCO2 levels following tube thoracostomy applied to PTX cases. conditions: Pneumothorax studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 43 type: ACTUAL name: End-tidal CO2 monitor measure: ETCO2-0 measure: ΔETCO2-1 measure: ΔETCO2-2 measure: ETCO2-1 measure: ETCO2-2 sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Bilkent Şehir Hastanesi city: Ankara state: Çankaya zip: 06170 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06276738 id: Adenocyte 102 briefTitle: The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2034-03-01 date: 2034-05-01 date: 2024-02-26 date: 2024-02-29 name: Adenocyte, LLC class: INDUSTRY briefSummary: Evaluate LINFU® in patients who exhibit signs or symptoms (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) suggestive of pancreatic cancer (PDAC) or have evidence of imaging studies suggestive of PDAC. conditions: Pancreatic Cancer conditions: Jaundice conditions: Abdominal Neoplasm studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas) measure: The number of pancreatic ductal adenocarcinomas identified only with LINFU® will be compared to standard screening methods measure: The change in size of pancreatic ductal adenocarcinomas identified only with LINFU® will be determined measure: Determine the number of patients with pancreatic ductal adenocarcinoma identified only with LINFU® that require medical or surgical intervention measure: Yearly survival rate of patients with pancreatic ductal adenocarcinomas identified only with LINFU® sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06276712 id: UNISS_PHD_Osstem_5 briefTitle: RCT Comparing KS Versus TS for Ovedenture overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-12-30 date: 2028-01-30 date: 2024-02-26 date: 2024-02-26 name: Università degli Studi di Sassari class: OTHER name: Dr. Dario Melodia name: Dr. Milena Pisano name: Dr. Aurea Lumbau name: Prof. Silvio Mario Meloni name: Prof. Edoardo Baldoni briefSummary: To evaluate the clinical and radiographic outcomes of KS implants used to rehabilitate edentulous mandible with dental-retained overdentures, and to compare it with same treatment on TS implants conditions: Dental Implant conditions: Dental Implant-Abutment Design conditions: Edentulous Jaw studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A multicenters, randomized controlled trial. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: A blinded (when possible) outcome assessor will evaluate all the outcomes and will take the radiogram for centralized analysis. whoMasked: OUTCOMES_ASSESSOR count: 48 type: ESTIMATED name: Implant placement with 3.5 mm diameter KS implants. name: Implant placement with 3.5 mm diameter TS implants. measure: Number of implant failure measure: Number of prosthesis failure measure: Number of complications measure: Rate of implant stability measure: Peri-implant marginal bone level changes measure: Patient satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False